News_Tianrui Biopharm|API|INTERMEDIATES

NEWS

Company News

Industry News

Home page

2025-12-11

Pioneering Achievement! Yichang Tianrui's Osimertinib Mesylate Secures Breakthrough Status, Leading the Future of High-End Pharmaceutical APIs

high quality API-Osimertinib Mesylate

2025-11-10

Exhibition Summary Report: Yichang Tianrui Biopharm Co., Ltd successful attented CPHI Frankurt 2025

2025-12-12

Yichang Renfu has been successfully included in the Hubei Province 2025 5G Factory List.

The Hubei Provincial Department of Economy and Information Technology officially released the 2025 5G Factory Directory, and the “Yichang Renfu 5G Smart Factory” project was smoothly selected.

Yichang Tianrui Biopharm Showcases Specialty API and CDMO Expertise at Jinan Pharma Partnering Forum

YICHANG, China – October 20, 2025 – Yichang Tianrui Biopharm Co., Ltd., a wholly-owned subsidiary of Humanwell Group, successfully exhibited at the prestigious Jinan Pharma Partnering Forum, held at the Sheraton Jinan Hotel on October 16-17, 2025.

2025/10

Strengthening the Safety Lifeline, Forging "Robust" Emergency Response Capabilities—Tianrui Pharmaceutical's Labor Competition Concludes Successfully

2025/10

Yichang Renfu Pharmaceutical's Flurbiprofen Axetil Injection Receives Marketing Approval

2025/09

Yichang Renfu Pharmaceutical's Remimazolam Tosylate for Injection Receives Approval for New Indication

Yichang Renfu Pharmaceutical has received the Drug Registration Certificate for Remimazolam Besylate for Injection issued by the National Medical Products Administration, approving the addition of a new indication for this product: "Used as a sedative for sedation during mechanical ventilation in intensive care."

2025/09

Yichang Renfu Pharmaceutical's heavy tartrate norepinephrine injection approved for market launch

Recently, the parent company Yichang Renfu Pharmaceutical Co., Ltd. received the Drug Registration Certificate for the heavy tartrate norepinephrine injection approved and issued by the National Medical Products Administration. This product was approved for market launch as a Category 3 chemical drug, with a specification of 4ml:8mg, and is considered to have passed the consistency evaluation.

2025/09

Moment of glory! Renfu Tianrui Pharmaceutical showcased at the 2025 Suzhou CMC Conference, winning two awards

2025/08

The parent company, Yichang Renfu Pharmaceutical's, rivastigmine transdermal patch has been approved for market.

2025/08

The parent company, Yichang Renfu Pharmaceutical's, rivastigmine transdermal patch has been approved for market.

Yichang Renfu Pharmaceutical Co., Ltd. received the Drug Registration Certificate for its rivastigmine transdermal patch from the National Medical Products Administration.

2025/07

API

Lumateperone Tosylate

Granisetron

Naltrexone

Gadoxetate Disodium

Landiolol hydrochloride

Fosaprepitant Dimeglumine

Flurbiprofen Axetil

Regadenoson

INTERMEDIATES

N-[4-bromo-2-(pyridine-2-carbonyl)phenyl]-2-chloroacetamide

(3S)-(7-BroMo-2-0xo-5-pyridin-2-y1-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)-propionic acid Methyl ester

(1R)-1-[2-bromo-6-(difluoromethoxy)phenyl]-7-chloro-2,3-dihydro-1H-Pyrrolo[1,2-a]benzimidazol-3-amine

(1R)-1-[2-bromo-6-(difluoromethoxy)phenyl]-7-chloro-2,3-dihydro-1H-Pyrrolo[1,2-a]benzimidazol-3-ol

Ethyl (βR)-β-amino-2-bromo-6-(difluoromethoxy)benzenepropanoate

2-(2-amino-5-bromobenzoyl)pyridine

ABOUT US

CONTACT

Add：66 Tianjiahe Avenue, Baiyang Town, Baiyang,Industrial Park, High-tech Zone,Yichang City, Hubei Province, China.
Tel：+86-717-4065884 +86-717-4065888

E-mail：yctr@renfu.com.cn

WhatsApp：13714525239

Tel：+86-(0)717-4065884